Literature DB >> 10678452

Characteristics of AMD patients with low vision receiving visual rehabilitation.

R A Schuchard1, S Naseer, K de Castro.   

Abstract

The purpose of this retrospective study done on 255 AMD patients evaluated at a low vision rehabilitation service was: 1) to describe the visual function characteristics (VFCs) of AMD patients presenting to visual rehabilitation, 2) to document changes in these VFCs between initial and follow-up rehabilitation visits, and 3) to investigate the relationship of the VFCs found at rehabilitation intake to the length of time between initial diagnosis and initial rehabilitation visit. Standard clinical testing (visual acuity and contrast sensitivity) as well as Scanning Laser Ophthalmoscope (SLO) visual function testing were performed to determine visual function including: 1) macular perimetry for scotoma boundary mapping and 2) PRL (preferred retinal locus) location and abilities in fixation, saccadic, and pursuit eye movements. The difference between the first and second visit VFCs were compared to the length of time between visits for 44 of the 255 patients returning for a second visit 0.5 to 4.5 years later. Finally, the initial date of AMD diagnosis was found for 51 of the 255 patients to analyze VFCs as a function of the time duration between diagnosis and the intake to the rehabilitation. Most VFCs had a wide range of results at initial intake to rehabilitation, while all patients had significant visual impairment by 24 months after initial diagnosis. The majority of low vision patients with AMD have bilateral central scotomas with the corresponding visual function and ADL problems that can often be overcome with visual rehabilitation.

Entities:  

Mesh:

Year:  1999        PMID: 10678452

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  22 in total

1.  Accessibility attributes of blood glucose meter and home blood pressure monitor displays for visually impaired persons.

Authors:  Morgan V Blubaugh; Mark M Uslan
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

2.  Effects of unsteady fixation on multifocal electroretinogram (mfERG).

Authors:  Patrick H W Chu; Henry H L Chan; Susan J Leat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-21       Impact factor: 3.117

3.  Use of multiple preferred retinal loci in Stargardt's disease during natural tasks: a case study.

Authors:  Brian Sullivan; Jelena Jovancevic-Misic; Mary Hayhoe; Gwen Sterns
Journal:  Ophthalmic Physiol Opt       Date:  2008-03       Impact factor: 3.117

4.  Home lighting assessment for clients with low vision.

Authors:  Monica S Perlmutter; Anjali Bhorade; Mae Gordon; Holly Hollingsworth; Jack E Engsberg; M Carolyn Baum
Journal:  Am J Occup Ther       Date:  2013 Nov-Dec

5.  How do flanking objects affect reaching and grasping behavior in participants with macular disorders?

Authors:  Shahina Pardhan; Carmen Gonzalez-Alvarez; Ahalya Subramanian; Susana T L Chung
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-28       Impact factor: 4.799

6.  A study of eccentric viewing training for low vision rehabilitation.

Authors:  Jae Hoon Jeong; Nam Ju Moon
Journal:  Korean J Ophthalmol       Date:  2011-11-22

Review 7.  Functional and cortical adaptations to central vision loss.

Authors:  Sing-Hang Cheung; Gordon E Legge
Journal:  Vis Neurosci       Date:  2005 Mar-Apr       Impact factor: 3.241

8.  The use of the scanning laser ophthalmoscope in the evaluation of amblyopia (an American Ophthalmological Society thesis).

Authors:  David A Johnson
Journal:  Trans Am Ophthalmol Soc       Date:  2006

9.  Dependence of reading speed on letter spacing in central vision loss.

Authors:  Susana T L Chung
Journal:  Optom Vis Sci       Date:  2012-09       Impact factor: 1.973

10.  Preferred retinal locus in macular disease: characteristics and clinical implications.

Authors:  Vivienne C Greenstein; Rodrigo A V Santos; Stephen H Tsang; R Theodore Smith; Gaetano R Barile; William Seiple
Journal:  Retina       Date:  2008-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.